

Paolo Macor

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8655104/paolo-macor-publications-by-citations.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

64
papers

1,942
citations

22
h-index

43
g-index

65
ext. papers

2,268
ext. citations

5.6
avg, IF

4.36
L-index

| # | Paper | IF | Citations |
|----|--|------|-----------|
| 64 | Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. <i>Blood</i> , 2005 , 106, 2340-6 | 2.2 | 256 |
| 63 | Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. <i>Blood</i> , 2014 , 124, 1715-26 | 2.2 | 220 |
| 62 | Complement in human diseases: Lessons from complement deficiencies. <i>Molecular Immunology</i> , 2009 , 46, 2774-83 | 4.3 | 216 |
| 61 | In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. <i>Cancer Research</i> , 2007 , 67, 10556-63 | 10.1 | 131 |
| 60 | A non-complement-fixing antibody to β glycoprotein I as a novel therapy for antiphospholipid syndrome. <i>Blood</i> , 2014 , 123, 3478-87 | 2.2 | 98 |
| 59 | The development of atypical hemolytic uremic syndrome depends on complement C5. <i>Journal of the American Society of Nephrology: JASN</i> , 2011 , 22, 137-45 | 12.7 | 89 |
| 58 | Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. <i>European Journal of Immunology</i> , 2005 , 35, 2175-83 | 6.1 | 79 |
| 57 | Complement as effector system in cancer immunotherapy. <i>Immunology Letters</i> , 2007 , 111, 6-13 | 4.1 | 60 |
| 56 | Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery. <i>Blood</i> , 2016 , 127, 365-7 | 2.2 | 51 |
| 55 | C7 is expressed on endothelial cells as a trap for the assembling terminal complement complex and may exert anti-inflammatory function. <i>Blood</i> , 2009 , 113, 3640-8 | 2.2 | 38 |
| 54 | Treatment of experimental arthritis by targeting synovial endothelium with a neutralizing recombinant antibody to C5. <i>Arthritis and Rheumatism</i> , 2012 , 64, 2559-67 | | 37 |
| 53 | The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studies. <i>European Journal of Immunology</i> , 2002 , 32, 2773-82 | 6.1 | 37 |
| 52 | Simple scale-up of recombinant antibody production using an UCOE containing vector. <i>New Biotechnology</i> , 2012 , 29, 477-84 | 6.4 | 35 |
| 51 | Cubosomes for in vivo fluorescence lifetime imaging. <i>Nanotechnology</i> , 2017 , 28, 055102 | 3.4 | 32 |
| 50 | Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma. <i>Cancer Research</i> , 2006 , 66, 3876-83 | 10.1 | 31 |
| 49 | Cubosomes stabilized by a polyphosphoester-analog of Pluronic F127 with reduced cytotoxicity. <i>Journal of Colloid and Interface Science</i> , 2020 , 580, 286-297 | 9.3 | 29 |
| 48 | Critical Role and Therapeutic Control of the Lectin Pathway of Complement Activation in an Abortion-Prone Mouse Mating. <i>Journal of Immunology</i> , 2015 , 195, 5602-7 | 5.3 | 28 |

| | | | |
|----|---|------|----|
| 47 | Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic Implications. <i>Frontiers in Immunology</i> , 2018 , 9, 1388 | 8.4 | 28 |
| 46 | New potential therapeutic approach for the treatment of B-Cell malignancies using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles. <i>PLoS ONE</i> , 2013 , 8, e74216 | 3.7 | 27 |
| 45 | Selective therapeutic control of C5a and the terminal complement complex by anti-C5 single-chain Fv in an experimental model of antigen-induced arthritis in rats. <i>Arthritis and Rheumatism</i> , 2007 , 56, 1187-97 | | 27 |
| 44 | Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers. <i>Arthritis Research and Therapy</i> , 2016 , 18, 111 | 5.7 | 24 |
| 43 | In Vivo Biodistribution and Lifetime Analysis of Cy5.5-Conjugated Rituximab in Mice Bearing Lymphoid Tumor Xenograft Using Time-Domain Near-Infrared Optical Imaging. <i>Molecular Imaging</i> , 2008 , 7, 7290.2008.00028 | 3.7 | 23 |
| 42 | Prevention of arthritis by locally synthesized recombinant antibody neutralizing complement component C5. <i>PLoS ONE</i> , 2013 , 8, e58696 | 3.7 | 22 |
| 41 | Posttransplant ischemia-reperfusion injury in transplanted heart is prevented by a minibody to the fifth component of complement. <i>Transplantation</i> , 2008 , 86, 1445-51 | 1.8 | 22 |
| 40 | Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies. <i>International Journal of Nanomedicine</i> , 2015 , 10, 4099-109 | 7.3 | 21 |
| 39 | New insight into antiphospholipid syndrome: antibodies to β glycoprotein I-domain 5 fail to induce thrombi in rats. <i>Haematologica</i> , 2019 , 104, 819-826 | 6.6 | 21 |
| 38 | Complement as a Biological Tool to Control Tumor Growth. <i>Frontiers in Immunology</i> , 2018 , 9, 2203 | 8.4 | 19 |
| 37 | An update on the xenograft and mouse models suitable for investigating new therapeutic compounds for the treatment of B-cell malignancies. <i>Current Pharmaceutical Design</i> , 2008 , 14, 2023-39 | 3.3 | 17 |
| 36 | The Dual Role of the Liver in Nanomedicine as an Actor in the Elimination of Nanostructures or a Therapeutic Target. <i>Journal of Oncology</i> , 2020 , 2020, 4638192 | 4.5 | 16 |
| 35 | Targeting CD34 cells of the inflamed synovial endothelium by guided nanoparticles for the treatment of rheumatoid arthritis. <i>Journal of Autoimmunity</i> , 2019 , 103, 102288 | 15.5 | 14 |
| 34 | Humoral immunotherapy of multiple myeloma: perspectives and perplexities. <i>Expert Opinion on Biological Therapy</i> , 2010 , 10, 863-73 | 5.4 | 14 |
| 33 | Phage display technology for human monoclonal antibodies. <i>Methods in Molecular Biology</i> , 2014 , 1060, 277-95 | 1.4 | 13 |
| 32 | Targeted Delivery of Neutralizing Anti-C5 Antibody to Renal Endothelium Prevents Complement-Dependent Tissue Damage. <i>Frontiers in Immunology</i> , 2017 , 8, 1093 | 8.4 | 13 |
| 31 | Multiple-Organ Complement Deposition on Vascular Endothelium in COVID-19 Patients. <i>Biomedicines</i> , 2021 , 9, | 4.8 | 13 |
| 30 | In vivo biodistribution and lifetime analysis of cy5.5-conjugated rituximab in mice bearing lymphoid tumor xenograft using time-domain near-infrared optical imaging. <i>Molecular Imaging</i> , 2008 , 7, 272-82 | 3.7 | 13 |

| | | | |
|----|--|------|----|
| 29 | Mutations in the 3'Untranslated region of are associated with low CD20 expression levels chronic lymphocytic leukemia. <i>Haematologica</i> , 2017 , 102, e305-e309 | 6.6 | 11 |
| 28 | Evidence of complement activation in the thrombotic small vessels of a patient with catastrophic antiphospholipid syndrome treated with eculizumab. <i>Autoimmunity Reviews</i> , 2019 , 18, 561-563 | 13.6 | 11 |
| 27 | The J-elongated conformation of β 2-glycoprotein I predominates in solution: implications for our understanding of antiphospholipid syndrome. <i>Journal of Biological Chemistry</i> , 2020 , 295, 10794-10806 | 5.4 | 11 |
| 26 | Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia. <i>Journal of Hematology and Oncology</i> , 2014 , 7, 79 | 22.4 | 11 |
| 25 | A new approach for the treatment of CLL using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles. <i>Nano Research</i> , 2016 , 9, 537-548 | 10 | 10 |
| 24 | Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia. <i>Oncotarget</i> , 2017 , 8, 3274-3288 | 3.3 | 10 |
| 23 | Multi-organ complement deposition in COVID-19 patients 2021 , | | 9 |
| 22 | Complement system and phagocytosis in a colonial protochordate. <i>Developmental and Comparative Immunology</i> , 2020 , 103, 103530 | 3.2 | 7 |
| 21 | Effects of eEF1A1 targeting by aptamer/siRNA in chronic lymphocytic leukaemia cells. <i>International Journal of Pharmaceutics</i> , 2020 , 574, 118895 | 6.5 | 7 |
| 20 | Complement Activation and Thrombin Generation by MBL Bound to β -Glycoprotein I. <i>Journal of Immunology</i> , 2020 , 205, 1385-1392 | 5.3 | 7 |
| 19 | Invasive meningococcal disease in three siblings with hereditary deficiency of the 8(th) component of complement: evidence for the importance of an early diagnosis. <i>Orphanet Journal of Rare Diseases</i> , 2016 , 11, 64 | 4.2 | 7 |
| 18 | Exploratory study on the effects of biodegradable nanoparticles with drugs on malignant B cells and on a human/mouse model of Burkitt lymphoma. <i>Current Clinical Pharmacology</i> , 2010 , 5, 246-50 | 2.5 | 5 |
| 17 | High fecal calprotectin levels are associated with SARS-CoV-2 intestinal shedding in COVID-19 patients: A proof-of-concept study. <i>World Journal of Gastroenterology</i> , 2021 , 27, 3130-3137 | 5.6 | 5 |
| 16 | Meniscal Ossicles as micro-CT Imaging Biomarker in a Rodent Model of Antigen-Induced Arthritis: a Synchrotron-Based X-ray Pilot Study. <i>Scientific Reports</i> , 2017 , 7, 7544 | 4.9 | 4 |
| 15 | Nanoparticles-Based Oligonucleotides Delivery in Cancer: Role of Zebrafish as Animal Model. <i>Pharmaceutics</i> , 2021 , 13, | 6.4 | 3 |
| 14 | An allosteric redox switch in domain V of β 2-glycoprotein I controls membrane binding and anti-domain I autoantibody recognition. <i>Journal of Biological Chemistry</i> , 2021 , 297, 100890 | 5.4 | 3 |
| 13 | The terminal complement pathway is activated in septic but not in aseptic shoulder revision arthroplasties. <i>Journal of Shoulder and Elbow Surgery</i> , 2018 , 27, 1837-1844 | 4.3 | 2 |
| 12 | Complement Component 3 expressed by the endometrial ectopic tissue is involved in the endometriotic lesion formation through mast cell activation | | 1 |

| | | | |
|----|---|------|---|
| 11 | Constitutive PSGL-1 Correlates with CD30 and TCR Pathways and Represents a Potential Target for Immunotherapy in Anaplastic Large T-Cell Lymphoma. <i>Cancers</i> , 2021 , 13, | 6.6 | 1 |
| 10 | Alterations in Trabecular Bone Architecture and Cartilages in Rats with Antigen-Induced Arthritis (AIA) Resulting from Synchrotron-Based X-Ray Imaging Analysis. <i>IFMBE Proceedings</i> , 2016 , 409-413 | 0.2 | 1 |
| 9 | The Inflammatory Feed-Forward Loop Triggered by the Complement Component C3 as a Potential Target in Endometriosis. <i>Frontiers in Immunology</i> , 2021 , 12, 693118 | 8.4 | 1 |
| 8 | Consumption of complement in a 26-year-old woman with severe thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. <i>Journal of Autoimmunity</i> , 2021 , 124, 102728 | 15.5 | 1 |
| 7 | Markers of complement activation in plasma during quiescent phases in patients with catastrophic antiphospholipid syndrome. <i>Blood</i> , 2021 , 137, 2989-2992 | 2.2 | 0 |
| 6 | New advances in chronic lymphocytic leukemia treatment: Biodegradable ZnO hybrid cluster nanoparticle as antineoplastic agents 2019 , 409-430 | | |
| 5 | Hereditary Deficiency of the Second Component of Complement: Early Diagnosis and 21-Year Follow-Up of a Family. <i>Medicina (Lithuania)</i> , 2020 , 56, | 3.1 | |
| 4 | The complement system at the feto-maternal interface: friend or foe?. <i>American Journal of Reproductive Immunology</i> , 2002 , 48, 142-143 | 3.8 | |
| 3 | Targeted Nanoparticles for the Delivery of Antagomir17: New Approach for the Treatment of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015 , 126, 5293-5293 | 2.2 | |
| 2 | Mutations at 3'Untranslated Region (3'UTR) of NOTCH1 Are Associated with Low CD20 Expression Levels in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016 , 128, 306-306 | 2.2 | |
| 1 | New Therapeutic Approach for the Treatment of B-Cell Disorders Using Chlorambucil/Hydroxychloroquine-Loaded AntiCD20 Nanoparticles. <i>Blood</i> , 2012 , 120, 158-158 | 2.2 | |